Prof. AYŞE ELİF ANIL YAĞCIOĞLU

Personal Information

Office Phone: +90 312 305 1874
Office Phone: +90 312 305 1873
Email: eanil@hacettepe.edu.tr
Web: https://avesis.hacettepe.edu.tr/eanil

International Researcher IDs
ORCID: 0000-0002-3269-150X
Publons / Web Of Science ResearcherID: I-9142-2013
ScopusID: 8415315300
Yoksis Researcher ID: 26336

Education Information

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 1993 - 1998

Foreign Languages

English, C1 Advanced

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Psychiatry

Academic Titles / Tasks

Professor, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2010 - Continues
Associate Professor, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2004 - 2010
Lecturer PhD, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2000 - 2004
Expert, Vanderbilt University, Tıp Fakültesi, Psikofarmakoloji Birimi, 1999 - 2000
Research Assistant, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 1993 - 1998

Academic and Administrative Experience

Hacettepe Üniversitesi, Hacettepe Tıp Fakültesı, 2014 - 2017
Hacettepe Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2011 - 2014

Courses

KONSÜLTASYON LİYEZON PSİKİYATRİSİ İÇİN LABORATUAR, Postgraduate, 2017 - 2018, 2016 - 2017
KONSÜLTASYON LİYEZON PSİKİYATRİSİNDE PSİKOFARMAKOLOJİ, Postgraduate, 2017 - 2018

PSİKİYATRİDE BELİRTİ VE BULGULAR, Undergraduate, 2017 - 2018, 2016 - 2017
KONSÜLTASYON LİYEZON PSİKİYATRİSİNDE KADIN HASTALIKLARI VE DOĞUM, Postgraduate, 2017 - 2018
KONSÜLTASYON LİYEZON PSİKİYATRİSİ İÇİN HASTA İLE GÖRÜŞMEDE TEMEL KAVRAMLAR, Postgraduate, 2017 - 2018, 2016 - 2017
KONSÜLTASYON LİYEZON PSİKİYATRİSİ İÇİN PSİKOFARMAKOLOJİ, Postgraduate, 2017 - 2018, 2016 - 2017
KONSÜLTASYON LİYEZON PSİKİYATRİSİ İÇİN PSİKOTİK BOZUKLUKLAR, Postgraduate, 2017 - 2018, 2016 - 2017
KONSÜLTASYON LİYEZON PSİKİYATRİSİ İÇİN KADIN HASTALIKLARI VE DOĞUM, Postgraduate, 2017 - 2018, 2016 - 2017
PSİKİYATRİDE SOMATİK TEDAVİLER, Undergraduate, 2017 - 2018, 2016 - 2017

Published journal articles indexed by SCI, SSCI, and AHCI

I. **Natural language processing for defining linguistic features in schizophrenia: A sample from Turkish speakers**
Çabuk T., Sevim N., MUTLU E., ANIL YAĞCIOĞLU A. E., Koç A., Toulopoulou T.
Schizophrenia Research, vol.266, pp.183-189, 2024 (SCI-Expanded)

II. **Validity and Reliability Study of Turkish Version of Clinical Assessment Interview for Negative Symptoms (CAINS)**
Vayisoğlu S., KARAHAN S., GÜREL Ş. C., ANIL YAĞCIOĞLU A. E.
Noropsikiyatri Arsivi, vol.61, no.1, pp.59-65, 2024 (SCI-Expanded)

III. **Escaping the Long Shadow Cast by Agranulocytosis: Reflections on Clozapine Pharmacovigilance Focused on the United Kingdom.**
de Leon J., Arrojo-Romero M., Verdoux H., Ruan C., Schoretsanitis G., Rohde C., Cohen D., Schulte P. F. J., Kim S. H., Cotes R. O., et al.
Journal of clinical psychopharmacology, vol.43, pp.239-245, 2023 (SCI-Expanded)

IV. **Hodgkin Lymphoma in Patients Receiving Clozapine Treatment: 2 Case Reports and Literature Review.**
Doğan M. K., Erdoğan N. O., ERTUĞRUL A., Yağcioğlu A. E., YAZICI M. S.
Journal of clinical psychopharmacology, vol.43, no.2, pp.180-183, 2023 (SCI-Expanded)

V. **Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition**
Schoretsanitis G., ANIL YAĞCIOĞLU A. E., Ruan C., Eap C. B., Molden E., Baptista T., Clark S. R., Fernandez-Egea E., Kim S. H., Lane H., et al.
Schizophrenia Research, 2023 (SCI-Expanded)

VI. **Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies**
Ruan C., Olmos I., Ricciardi C., Schoretsanitis G., Vincent P. D., ANIL YAĞCIOĞLU A. E., Eap C. B., Baptista T., Clark S. R., Fernandez-Egea E., et al.
Schizophrenia Research, 2023 (SCI-Expanded)

VII. **Effect of clozapine on suicidality in patients with schizophrenia at a university hospital in Turkey**
Gürcan G., Şenol Ş. H., Yağcıoğlu A. E., ERTUĞRUL A.
Schizophrenia Research, 2023 (SCI-Expanded)

VIII. **A systematic chart review of pharmacological interventions in patients with clozapine-induced hypersalivation**
MUTLU E., ÖZÇELİK EROĞLU E., COŞKUN F. M., KOÇYİĞİT D., CANPOLAT İ. K. N., AVCI H., ERTUĞRUL A., ANIL YAĞCIOĞLU A. E.
Schizophrenia Research, 2023 (SCI-Expanded)

IX. **Valproate, obesity and other causes of clozapine poor metabolism in the context of rapid titration may explain clozapine-induced myocarditis: A re-analysis of a Turkish case series El valproato, la**

obesidad y otras causas de metabolismo deficiente de la clozapina en el contexto de una titulación rápida de las dosis pueden explicar la miocarditis inducida por clozapina: un nuevo análisis de una serie de casos turca
ERTUĞRUL A., ANIL YAĞCIOĞLU A. E., Ağaoğlu E., Karakaşlı A. A., AK S., YAZICI M. S., Leon J. d.
Revista de Psiquiatria y Salud Mental, vol.15, no.4, pp.281-286, 2022 (SCI-Expanded)

X. **Combination With Long-Acting Injectable Antipsychotics and Utilization of Nonstandard Formulations as Compliance Enhancing Methods for Clozapine Users A Systematic Review and A Case Series**
Mutlu E., Dogan M. K., ERTUĞRUL A., ANIL YAĞCIOĞLU A. E.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol.42, no.3, pp.298-307, 2022 (SCI-Expanded)

XI. **Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders**
Okhuijsen-Pfeifer C., van der Horst M. Z., Bousman C. A., Lin B., van Eijk K. R., Ripke S., Ayhan Y., Babaoglu M. O., Bak M., Alink W., et al.
TRANSLATIONAL PSYCHIATRY, vol.12, no.1, 2022 (SCI-Expanded)

XII. **Renal effects of long-term lithium therapy, revisited**
Yazici M. K., Eroglu E. O., ERTUĞRUL A., ANIL YAĞCIOĞLU A. E., Agaoglu E., KARAHAN S., Eni N., SAĞLAM AYKUT D., Kavak O., ERDEM Y.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.37, no.2, 2022 (SCI-Expanded)

XIII. **An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels**
de Leon J., Schoretsanitis G., Smith R. L., Molden E., Solismaa A., Seppala N., Kopecek M., Svancer P., Olmos I., Ricciardi C., et al.
PHARMACOPSYCHIATRY, vol.55, no.02, pp.73-86, 2022 (SCI-Expanded)

XIV. **Comparison of Formal Thought Disorder in the Acute Episode of Schizophrenia and Manic Episode of Bipolar Affective Disorder**
Mutlu E., Gürkan Ş., Göka E., Yağcioğlu A. E.
Turk Psikiyatri Dergisi, vol.33, no.4, pp.223-232, 2022 (SSCI)

XV. **The cognitive aspect of formal thought disorder and its relationship with global social functioning and the quality of life of in schizophrenia**
MUTLU E., ABAOĞLU H., BARIŞKIN E., GÜREL Ş. C., ERTUĞRUL A., Yazici M. K., AKI E., ANIL YAĞCIOĞLU A. E.
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, vol.56, pp.1399-1410, 2021 (SCI-Expanded)

XVI. **Common Side Effects and Metabolic Syndrome due to Clozapine: Relationship with the Clinical Variables and Disability**
Gurcan G., Senol S. H., ANIL YAĞCIOĞLU A. E., KARAHAN S., ERTUĞRUL A.
TURK PSIKIYATRI DERGISI, vol.32, no.2, pp.87-99, 2021 (SSCI)

XVII. **Augmentation of Clozapine Due to Inadequate Treatment Response in Schizophrenia: Comparison of Patients with Augmented and Non-augmented Treatments**
Senol S. H., Gurcan G., ERTUĞRUL A., KARAHAN S., ANIL YAĞCIOĞLU A. E.
TURK PSIKIYATRI DERGISI, vol.32, no.1, pp.1-7, 2021 (SSCI)

XVIII. **Relapse in patients with serious mental disorders during the COVID-19 outbreak: a retrospective chart review from a community mental health center**
Mutlu E., Anil Yagcioglu A. E.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, vol.271, no.2, pp.381-383, 2021 (SCI-Expanded)

XIX. **Predictors of discontinuation and hospitalization during long-acting injectable antipsychotic treatment in patients with schizophrenia spectrum disorder**
Ucok A., Yagcioglu E. A., AYDIN M., Kara I. A., Erbasan V., TÜRKOĞLU Ö., Ergun S., Chousein M. G., OKTAR ERDOĞAN N., Ucar N., et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, vol.36, no.2, pp.89-96, 2021 (SCI-Expanded)

XX. **Clinical risk factors, phenomenology and the impact of clozapine induced obsessive compulsive**

symptoms.
Gürcan G., Şenol Ş. H., Yağcıoğlu A. E., Ertuğrul A.
Psychiatry research, vol.296, pp.113665, 2021 (SCI-Expanded)

XXI. **A follow-up study of metabolic syndrome in schizophrenia**
Yoca G., ANIL YAĞCIOĞLU A. E., Eni N., KARAHAN S., TÜRKOĞLU İ., Akal Yıldız E., MERCANLIGİL S. M., YAZICI M. K.
European Archives Of Psychiatry And Clinical Neuroscience, vol.270, pp.611-618, 2020 (SCI-Expanded)

XXII. **Weight Loss Associated with Clozapine: A Case Report**
Mutlu E., Eroglu E. O., AYHAN Y., Yagcioglu E. A., Yazici M. K.
TURK PSIKIYATRI DERGISI, vol.31, no.2, pp.143-145, 2020 (SSCI)

XXIII. **The Effect of Life Skills Training on Functioning in Schizophrenia: A Randomized Controlled Trial**
ABAOĞLU H., Mutlu E., AK S., AKI E., ANIL YAĞCIOĞLU A. E.
TURK PSIKIYATRI DERGISI, vol.31, no.1, pp.50-58, 2020 (SSCI)

XXIV. **Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis**
Vayisoglu S., KARAHAN S., ANIL YAĞCIOĞLU A. E.
TURK PSIKIYATRI DERGISI, vol.30, no.4, pp.253-259, 2019 (SSCI)

XXV. **A comparative study of detection of myocarditis induced by clozapine: With and without cardiac monitoring**
ANIL YAĞCIOĞLU A. E., ERTUĞRUL A., KARAKAŞLI A. A., Ağaoğlu E., AK S., KARAHAN S., YAZICI M. K.
Psychiatry Research, vol.279, pp.90-97, 2019 (SCI-Expanded)

XXVI. **Examination of formal thought disorder and its clinical correlates with the Turkish Version of the Thought and Language Disorder Scale (TALD-TR) in schizophrenia**
MUTLU E., YAZICI M. K., BARIŞKIN E., ERTUĞRUL A., GÜREL Ş. C., Gürkan Ş., GÖKA E., ANIL YAĞCIOĞLU A. E.
Comprehensive Psychiatry, vol.93, pp.7-13, 2019 (SCI-Expanded)

XXVII. **Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia**
Ucok A., ANIL YAĞCIOĞLU A. E., Yıldız M., Kaymak Ulusoy S., SAKA M. C., Taşdelen R., ESEN DANACI A., Şenol Ş. H.
Psychiatry Research, vol.275, pp.149-154, 2019 (SCI-Expanded)

XXVIII. **Relation of the Allelic Variants of Multidrug Resistance Gene to Agranulocytosis Associated With Clozapine**
YAGCIOGLU A. E., Yoca G., AYHAN Y., KARACA R. O., Cevik L., MÜDERRİSOĞLU A., GÖKTAŞ M. A., ENI N., YAZICI M. S., Bozkurt A., et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol.36, no.3, pp.257-261, 2016 (SCI-Expanded)

XXIX. **Quetiapine Treatment for Self-Mutilation in Chorea-Acanthocytosis A Case Report**
AK S., GÜREL Ş. C., Bas D. F., Yagcioglu A. E.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol.35, no.2, pp.208-209, 2015 (SCI-Expanded)

XXX. **Quetiapine Treatment for Self Mutilation in Neuroacanthocytosis A Case Report**
AK S., GÜREL Ş. C., BAŞ D. F., ANIL YAĞCIOĞLU A. E.
Journal of Clinical Psychopharmacology, vol.35, pp.208-209, 2015 (SCI-Expanded)

XXXI. **Prediction of response to antipsychotic drugs in schizophrenia patients within the early phase of treatment**
YILDIZ M., YAZICI M. K., ANIL YAĞCIOĞLU A. E., KARAHAN S., Şevik A. E., GÜRSES N.
Bulletin of Clinical Psychopharmacology, vol.25, pp.390-398, 2015 (SCI-Expanded)

XXXII. **Augmentation Strategies in Patients with Schizophrenia Who Show Partial Response to Clozapine Treatment**
VAYISOĞLU S., ANIL YAĞCIOĞLU A. E.
TURK PSIKIYATRI DERGISI, vol.25, no.3, pp.201-211, 2014 (SSCI)

XXXIII. **A case of clozapine intoxication presenting with atypical NMS symptoms**
Kamis G. Z., AYHAN Y., BAŞAR K., ÖZER S., Yagcioglu A. E.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, vol.17, no.5, pp.819-821, 2014 (SCI-Expanded)

XXXIV. **INVESTIGATION OF THE ROLE OF ALLELIC VARIANTS OF MULTIDRUG RESISTANCE GENE (MDR1) ON CLOZAPINE RELATED LEUKOPENIA/AGRANULOCYTOSIS**

ANIL YAĞCIOĞLU A. E., YOCA G., Karaca R. O., ÇEVİK L., BABAOĞLU M. Ö., AYHAN Y., Eni N., Yazici M. K., BOZKURT A.
SCHIZOPHRENIA RESEARCH, vol.153, 2014 (SCI-Expanded)

XXXV. **Exome sequence analysis of Finnish patients with clozapine induced agranulocytosis**
TİWARİ A., NEED A., LOHOFF F., ZAİ C., CHOWDHURY N., MÜLLER D., PUTKONEN A., REPO TİİHONEN E., HALLİKAİNEN T., ANIL YAĞCIOĞLU A. E., et al.
Molecular Psychiatry, vol.19, pp.403-405, 2014 (SCI-Expanded)

XXXVI. **Language dependent performance on the letter fluency task in patients with schizophrenia**
SUMİYOSHİ C., ERTUĞRUL A., ANIL YAĞCIOĞLU A. E., ROY A., JAYATHİLAKE K., MİLBY A., MELTZER H. Y., SUMİYOSHİ T.
Schizophrenia Research, vol.152, pp.421-429, 2014 (SCI-Expanded)

XXXVII. **Escitalopram-induced Parkinsonism.**
Ak S., Yagcioglu A. E.
General hospital psychiatry, vol.36, no.1, 2014 (SCI-Expanded)

XXXVIII. **Escitalopram induced Parkinsonism**
AK S., ANIL YAĞCIOĞLU A. E.
General Hospital Psychiatry, vol.36, pp.126, 2014 (SCI-Expanded)

XXXIX. **Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) in Two Siblings with Neuropsychiatric Symptoms**
DERİCİOĞLU N., Vural A., AGAYEYA N., BAŞAR K., YAGCIOGLU A. E., GURSOY-OZDEMIR Y.
PSYCHOSOMATICS, vol.54, no.6, pp.594-598, 2013 (SCI-Expanded)

XL. **Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy CADASIL in two siblings with neuropsychiatric symptoms**
DERİCİOĞLU N., VURAL A., AGAYEVA N., BAŞAR K., ANIL YAĞCIOĞLU A. E., GÜRSOY ÖZDEMİR Y.
Psychosomatics, vol.54, pp.594-598, 2013 (SCI-Expanded)

XLI. **Acute Psychosis and Depression Associated with Hypercalcemia A Case Report**
ÖZCAN H., ANIL YAĞCIOĞLU A. E., ŞEVİK A. E., ÜSTÜNDAĞ M. F.
Nöropsikiyatri Arşivi, vol.50, pp.75-77, 2013 (SCI-Expanded)

XLII. **Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment**
Vayisoglu S., Yagcioglu A. E., Yagcioglu S., KARAHAN S., Karci O., GÜREL Ş. C., YAZICI M. S.
SCHIZOPHRENIA RESEARCH, vol.143, no.1, pp.207-214, 2013 (SCI-Expanded)

XLIII. **Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment**
VAYISOĞLU S., ANIL YAĞCIOĞLU A. E., YAĞCIOĞLU S., KARAHAN S., KARCI O., GÜREL Ş. C., YAZICI M. K.
Schizophrneia Research, vol.143, pp.207-214, 2013 (SCI-Expanded)

XLIV. **LAMOTRIGINE AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA WHO SHOW PARTIAL RESPONSE TO CLOZAPINE TREATMENT**
Vayisoglu S., ANIL YAĞCIOĞLU A. E., ANIL YAĞCIOĞLU A. E., KARAHAN S., Karci O., Gurel C., Yazici M. K.
SCHIZOPHRENIA RESEARCH, vol.136, 2012 (SCI-Expanded)

XLV. **Neuropsychological Performance and Auditory Event Related Potentials in Schizophrenia Patients and their Siblings A Family Study**
ŞEVİK A. E., ANIL YAĞCIOĞLU A. E., YAĞCIOĞLU S., KARAHAN S., GÜRSES N., YILDIZ M.
Schizophrenia Research, vol.130, pp.195-202, 2011 (SCI-Expanded)

XLVI. **The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey**
YAZICI M. S., YAGCIOGLU A. E., ERTUĞRUL A., ENI N., KARAHAN S., KARAAGAOGLU E., TOKGÖZOĞLU S. L.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, vol.261, no.1, pp.69-78, 2011 (SCI-Expanded)

XLVII. **Agranulocytosis Related to Clozapine in Monozygotic Twins and Association With Allelic Variants of Multidrug Resistance Gene MDR1**
ANIL YAĞCIOĞLU A. E., İLHAN ÇETİN B., GÖKTAŞ M., BABAOĞLU M. Ö., Uz E., YAZICI M. K.

Journal Of Clinical Psychopharmacology, vol.31, pp.247-249, 2011 (SCI-Expanded)

XLVIII. **Semantic memory deficits based on category fluency performance in schizophrenia: Similar impairment patterns of semantic organization across Turkish and Japanese patients**
SUMIYOSHI C., ERTUĞRUL A., Yagcioglu A. E., SUMIYOSHI T.
PSYCHIATRY RESEARCH, vol.167, pp.47-57, 2009 (SCI-Expanded)

XLIX. **A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia**
Meltzer H. Y., Bobo W. V., Roy A., Jayathilake K., Chen Y., ERTUĞRUL A., YAGCIOGLU A. E., SMALL J. G.
JOURNAL OF CLINICAL PSYCHIATRY, vol.69, no.2, pp.274-285, 2008 (SCI-Expanded)

L. **A randomized double blind comparison of clozapine and high doseolanzapine in treatment resistant patients with schizophrenia**
MELTZER H. Y., BOBO W., ROY A., JAYATHİLAKE K., CHEN Y., ERTUĞRUL A., ANIL YAĞCIOĞLU A. E., SMALL J.
JOURNAL OF CLINICAL PSYCHIATRY, vol.69, pp.274-285, 2008 (SCI-Expanded)

LI. **Antipsikotik ilaçların etki mekanizmaları Şizofreni tedavisinde atipiklik bir üstünlük mü**
ANIL YAĞCIOĞLU A. E.
Türk Psikiyatri Dergisi, vol.18, pp.364-374, 2007 (SSCI)

LII. **[The mechanisms of action of antipsychotic drugs: is atypicality superior in schizophrenia treatment?].**
Anil Yağcioğlu A. E.
Turk psikiyatri dergisi = Turkish journal of psychiatry, vol.18, no.4, pp.364-74, 2007 (SSCI)

LIII. **A double blind study of combination of clozapine with risperidone in patients with schizophrenia effects on cognition**
AKDEDE B. B., ANIL YAĞCIOĞLU A. E., ALPTEKİN K., TURGUT T. İ., TÜMÜKLÜ M., YAZICI M. K., JAYATHİLAKE K., TUNCA Z., GÖĞÜŞ A.
Journal of Clinical Psychiatry, vol.67, pp.1912-1919, 2006 (SCI-Expanded)

LIV. **Clozapine alone versus clozapine and risperidone for refractory schizophrenia**
Meltzer H., ANIL YAĞCIOĞLU A. E., Akdede B.
NEW ENGLAND JOURNAL OF MEDICINE, vol.354, no.17, pp.1846-1847, 2006 (SCI-Expanded)

LV. **Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients**
Ertugrul A., YAGCIOGLU A. E., ENI N., YAZICI K.
PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.59, no.2, pp.219-222, 2005 (SCI-Expanded)

LVI. **Creutzfeldt-Jakob disease: A case that initiated with psychiatric symptoms**
KURNE A., Ertugrul A., YAGCIOGLU A. E., DEMIRCI E., YAZICI K., KANSU T.
TURK PSIKIYATRI DERGISI, vol.16, no.1, pp.55-59, 2005 (SSCI)

LVII. **Creutzfeldt Jakob disease A case that initiated with psychiatricsymptoms**
KURNE A., ERTUĞRUL A., ANIL YAĞCIOĞLU A. E., YAZICI M. K., DEMİRCİ E., KANSU T.
TURK PSIKIYATRI DERGISI, vol.16, pp.55-59, 2005 (SCI-Expanded)

LVIII. **A double blind controlled study of adjunctive treatment with risperidonein schizophrenic patients partially responsive to clozapine Efficacyand safety**
ANIL YAĞCIOĞLU A. E., AKDEDE B. B., TURGUT T. İ., TÜMÜKLÜ M., YAZICI M. K., ERTUĞRUL A., JAYATHİLAKE K., GÖĞÜŞ A., TUNCA Z., MELTZER H. Y.
JOURNAL OF CLINICAL PSYCHIATRY, vol.66, pp.63-72, 2005 (SCI-Expanded)

LIX. **A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety**
YAGCIOGLU A. E., AKDEDE B., TURGUT T., TUMUKLU M., YAZICI M., ALPTEKIN K., Ertugrul A., Jayathilake K., GOGUS A., TUNCA Z., et al.
JOURNAL OF CLINICAL PSYCHIATRY, vol.66, no.1, pp.63-72, 2005 (SCI-Expanded)

LX. **Venous thromboembolism and escitalopram**
KURNE A., Ertugrul A., YAGCIOGLU A. E., YAZICI K.
GENERAL HOSPITAL PSYCHIATRY, vol.26, no.6, pp.481-483, 2004 (SCI-Expanded)

LXI. **A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs - A survey of**

clozapine, risperidone, olanzapine, and quetiapine
Sumiyoshi T., Roy A., Anil A. E., Jayathilake K., Ertugrul A., Meltzer H.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol.24, no.3, pp.345-348, 2004 (SCI-Expanded)

LXII. **A Comparison of Incidence of Diabetes Mellitus Between Atypical Antipsychotic Drugs A Survey for Clozapine Risperidone Olanzapine and Quetiapine**
SUMİYOSHİ T., ROY A., ANIL A. E., JAYAHTİLAKE K., ERTUĞRUL A., MELTZER H. Y.
Journal of Clinical Psychopharmacology, vol.24, pp.345-348, 2004 (SCI-Expanded)

LXIII. **Severe hyperglycemia associated with electroconvulsive therapy**
Dağdelen S., Akın Atmaca A., Gürlek Ö. A., Tufan A., Güven E., Anıl Yağcıoğlu A. E.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, vol.27, pp.615, 2004 (SCI-Expanded)

LXIV. **A Double Blind Placebo Controlled Cross Over Trial of Adjunctive Donepezil for Cognitive Impairment in Schizophrenia**
TUĞAL Ö., YAZICI M. K., ANIL YAĞCIOĞLU A. E., GÖĞÜŞ A.
The International Journal of Neuropsychopharmacology, vol.7, pp.117-123, 2004 (SCI-Expanded)

LXV. **Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms**
SUMİYOSHİ T., ANIL A. E., JİN D., JAYATHİLAKE K., LEE M., MELTZER H. Y.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, vol.7, no.1, pp.1-8, 2004 (SCI-Expanded)

LXVI. **Re Examination of the Characteristics of the Deficit Schizophrenia Patients**
TİRYAKİ A., YAZICI M. K., ANIL A. E., KABAKÇI E., KARAAĞAOĞLU A. E., GÖĞÜŞ A.
European Archives of Psychiatry and Clinical Neuroscience, vol.253, pp.221-227, 2003 (SCI-Expanded)

LXVII. **Reexamination of the characteristics of the deficit schizophrenia patients**
TIRYAKI A., Yazici M. K., ANIL A. E., KABAKCI E., KARAAGAOGLU E., GOGUS A.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, vol.253, no.5, pp.221-227, 2003 (SCI-Expanded)

LXVIII. **The Turkish version of the Auditory Consonant Trigram Test as a measure of working memory: A normative study**
ANIL A. E., Kivircik B., BATUR S., KABAKÇI E., Kitias A., GÜVEN E., BAŞAR K., TURGUT T. İ., Arkar H.
CLINICAL NEUROPSYCHOLOGIST, vol.17, no.2, pp.159-169, 2003 (SCI-Expanded)

LXIX. **Venous Thromboembolism and Clozapine An Association Unresolved**
ANIL A. E., ÖZKAN B., ULUŞAHİN A.
General Hospital Psychiatry, vol.25, pp.59-60, 2003 (SCI-Expanded)

LXX. **The characteristics, treatment response, safety, and concominant medication use of patients receiving clozapine treatment**
Anil A. E., Turgut I., Kabakci E., Rezaki M., Gogus A.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol.12, 2002 (SCI-Expanded)

LXXI. **Is deficit syndrome a separate disease within the syndrome of schizophrenia?**
Yazici K., Tiryaki A., Anil A. E., Kabakci E., Godup A.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol.12, 2002 (SCI-Expanded)

LXXII. **[A review on augmentation of clozapine treatment].**
Anil A. E., Turgut I. T., Rezaki M., Göğüş A.
Turk psikiyatri dergisi = Turkish journal of psychiatry, vol.13, no.1, pp.65-77, 2002 (SCI-Expanded)

LXXIII. **Atipik Antipsikotiklere Bağlı Glukoz Metabolizması Bozuklukları**
ANIL A. E., MELTZER H. Y.
Türk Psikiyatri Dergisi, vol.12, pp.225-232, 2001 (SSCI)

LXXIV. **Şizofrenik Hastalarda Olanzapin ve Klorpromazinin Etki ve Güvenliğinin Karşılaştırılması**
KOSTAKOĞLU ., ALPTEKİN K., KIVIRCIK B. B., KABAKÇI E., TUNCA Z., GÖĞÜŞ A.
Türk Psikiyatri Dergisi, vol.12, pp.3-16, 2001 (SSCI)

LXXV. **Response Negative Symptoms Redux**
KOSTAKOGLU ., Meltzer H. Y.
Neuropsychopharmacology, vol.22, pp.662-664, 2000 (SCI-Expanded)

LXXVI. **Reliability and Validity of the Turkish version of the Positive and Negative Syndrome Scale Pozitif ve Negatif Sendrom Ölçeğinin PANSS Türkçe Uyarlamasının Geçerlik ve Güvenilirliği**
KOSTAKOĞLU A. E., BATUR S., TİRYAKİ A., GÖĞÜŞ A.
Türk Psikoloji Dergisi, vol.14, pp.23-34, 1999 (SSCI)

LXXVII. **Reliability and validity of the Turkish version of the Positive and Negative Syndrome Scale (PANSS)**
Kostakoglu E., Batur S., Tiryaki A., Gogus A.
TURK PSIKOLOJI DERGISI, vol.14, no.44, pp.23-34, 1999 (SSCI)

LXXVIII. **Early relapse of psychotic symptoms after an initial response to olanzapine**
KOSTAKOĞLU A. E., REZAKİ M., GÖĞÜŞ A.
ACTA PSYCHIATRICA SCANDINAVICA, vol.100, no.4, pp.312-314, 1999 (SCI-Expanded)

LXXIX. **Ketoacidosis as a side effect of clozapine A case report**
KOSTAKOĞLU A. E., YAZICI M. K., ERBAŞ A. T., GÜVENER DEMİRAĞ H. N.
ACTA PSYCHİATRİCA SCANDİNAVİCA, vol.93, pp.217-218, 1998 (SCI-Expanded)

Articles Published in Other Journals

I. **Şizofreni Bağlamında Psikotik Bozukluklarda Dayanıklılık**
MUTLU E., ANIL YAĞCIOĞLU A. E.
Psikiyatride Güncel, vol.12, no.4, pp.358-367, 2022 (Peer-Reviewed Journal)

II. **An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine**
de Leon J., Ruan C., Schoretsanitis G., Rohde C., Yagcioglu E. A., Baptista T., Kirilochev O. O., De las Cuevas C., Correll C. U.
GENERAL PSYCHIATRY, vol.35, no.3, 2022 (ESCI)

III. **Effects of the COVID -19 pandemic on patients with schizophrenia spectrum disorders.**
ÖZÇELİK EROĞLU E., ERDOĞAN İ. M., Yıldız M., ANIL YAĞCIOĞLU A. E., TÜRKOĞLU Ö., YALÇINKAYA O. K., ERTUĞRUL A., KARAHAN S., YAZICI M. K.
Acta Medica, 2022 (Peer-Reviewed Journal)

IV. **Bir Şizofreni Vakasında, Hastalık Sürecinin Erken Döneminde Abilify Maintena® Kullanımı**
ANIL YAĞCIOĞLU A. E.
Türkiye Klinikleri, pp.5-6, 2018 (Non Peer-Reviewed Journal)

V. **Psikofarmakolojik tedavilerin bilişsel işlevler üzerine etkisi**
AYHAN Y., ANIL YAĞCIOĞLU A. E.
Psikiyatride Güncel, vol.7, 2017 (Peer-Reviewed Journal)

VI. **VAK A Şizofreni**
GÜREL Ş. C., Karabucak B., ANIL YAĞCIOĞLU A. E.
Türkiye Kinikleri, vol.1, 2015 (Non Peer-Reviewed Journal)

VII. **Tedaviye Dirençli Şizofrenide Antipsikotikleri Güçlendirme Tedavileri ve Yeni Tedavi Yaklaşımları**
GÜREL Ş. C., ANIL YAĞCIOĞLU A. E.
Psikiyatride Güncel, vol.5, pp.314-329, 2015 (Peer-Reviewed Journal)

VIII. **Kardiyovasküler Hastalıklarda Cinsel İşlev Bozukluklarına Psikiyatrik Yaklaşım**
YILDIZ İ., ANIL YAĞCIOĞLU A. E.
Türk Kardiyoloji Seminerleri, vol.12, pp.169-180, 2012 (Non Peer-Reviewed Journal)

IX. **Carbamazepine Associated Prolonged Erection in a Patient with Bipolar Disorder**
ÖZCAN H., ANIL YAĞCIOĞLU A. E., ŞEVİK A. E., ÜSTÜNDAĞ M. F.
Journal of Mood Disorders, vol.2, pp.126-128, 2012 (Peer-Reviewed Journal)

X. **Antipsikotiklerin Kardiyak Yan Etkileri**
ANIL YAĞCIOĞLU A. E., ERTUĞRUL A.
Psikiyatride Güncel, vol.1, pp.251-265, 2011 (Peer-Reviewed Journal)

XI. **Koroner Yoğun Bakımda Deliriyum**

ANIL YAĞCIOĞLU A. E.
Türk Kardiyoloji Seminerleri, vol.9, pp.85-93, 2009 (Non Peer-Reviewed Journal)

XII. **Şizofreni Tedavisi ve Antipsikotik İlaçlar**
ANIL YAĞCIOĞLU A. E.
Türkiye Klinikleri Dahili Tıp Bilimleri Dergisi, vol.1, pp.49-56, 2005 (Non Peer-Reviewed Journal)

XIII. **Klozapin Kullanımına Bağlı EEG Değişiklikleri**
KARATAŞ KURŞUN H., DERİCİOĞLU N., Karabulut E., ANIL YAĞCIOĞLU A. E., Uluşahin A., Ciğer A.
Türk Nöroloji Dergisi, vol.10, pp.36-42, 2004 (ESCI)

XIV. **Combining Antipsychotics Is There Evidence for Efficacy**
MELTZER H. Y., KOSTAKOĞLU A. E.
Psychiatric Times, vol.17, pp.25-34, 2000 (Scopus)

XV. **Yeni Kuşak Antidepresanlar**
ANIL A. E., YAZICI M. K.
Hacettepe Tıp Dergisi, vol.31, pp.353-361, 2000 (Non Peer-Reviewed Journal)

XVI. **Negative Symptoms An Overview of the Concept and Response to Antipsychotic Drug Treatment**
KOSTAKOĞLU A. E., MELTZER H. Y.
Türkiye'de Psikiyatri, vol.1, pp.59-71, 1999 (Peer-Reviewed Journal)

Books & Book Chapters

I. **Antipsikotikler – Genel Özellikleri**
ANIL YAĞCIOĞLU A. E., MUTLU E.
in: Şizofreni ve Diğer Psikotik Bozuklukların Psikofarmakolojisi, Anıl Yağcıoğlu A. Elif, Soygür Haldun, Alptekin Köksal, Editor, Türkiye Psikiyatri Derneği Yayınları, Ankara, pp.59-92, 2023

II. **Klozapin: Özel Konumda Bir Antipsikotik**
ANIL YAĞCIOĞLU A. E., MUTLU E.
in: Şizofreni ve Diğer Psikotik Bozuklukların Psikofarmakolojisi, Anıl Yağcıoğlu A. Elif, Soygür Haldun, Alptekin Köksal, Editor, Türkiye Psikiyatri Derneği Yayınları, Ankara, pp.175-198, 2023

III. **Sanrılı Bozukluk**
Aylak İ., Anıl Yağcıoğlu A. E.
in: Genişletilmiş ve Güncellenmiş 3. Baskı. TPD Şizofreni ve Diğer Psikotik Bozukluklar., Esen Danacı A,Böke Ö,Saka MC,Erol A,Ulusoy Kaymak S, Editor, Türkiye Psikiyatri Derneği Yayınları, Ankara, pp.224-241, 2021

IV. **Şizofrenide elektrokonvulzif tedavi ve diğer beyin uyarımı tedavileri**
Gürel Ş. C., Anıl Yağcıoğlu A. E.
in: Genişletilmiş ve Güncellenmiş 3. Baskı TPD Şizofreni ve Diğer Psikotik Bozukluklar, Esen Danacı A,Böke Ö,Saka MC,Erol A,Ulusoy Kaymak S, Editor, Türkiye Psikiyatri Derneği Yayınları, Ankara, pp.503-523, 2021

V. **Şizofrenide Tedaviye Direnç**
Anıl Yağcıoğlu A. E., Gürel Ş. C.
in: Genişletilmiş ve Güncellenmiş 3. Baskı. TPD Şizofreni ve Diğer Psikotik Bozukluklar., Esen Danacı A,Böke Ö,Saka MC,Erol A, Editor, Türkiye Psikiyatri Derneği Yayınları, Ankara, pp.524-550, 2021

VI. **Şizofreni: Kavramın Tarihçesi, Epidemiyoloji, Klinik Özellikler ve Seyir**
ANIL YAĞCIOĞLU A. E., AYHAN Y.
in: Temel ve Klinik Psikiyatri Kitabı, Karamustafalıoğlu Mustafa, Editor, Güneş Tıp Kitabevleri, Ankara, pp.201-215, 2018

VII. **Şizofrenide elektrokonvulzif tedavi ve diğer beyin uyarımı tedavileri**
GÜREL Ş. C., ANIL YAĞCIOĞLU A. E.
in: Şizofreni ve Diğer Psikotik Bozukluklar :Temel Kitap, Esen-Danacı A, Böke Ö, Saka MC, Erol A, Ulusoy Kaymak S, Editor, Türkiye Psikiyatri Derneği Yayınları, pp.473-493, 2018

VIII. **Kadın Hastalıkları ve Doğumda Psikoloji ve Psikiyatrinin Yeri**
ANIL YAĞCIOĞLU A. E., AYHAN Y.

in: Temel Kadın Hastalıkları ve Doğum Bilgisi, AYHAN Ali, BOZDAĞ Gürkan, DEREN Özgür, ESİNLER İbrahim, HARMANLI Özgür, ÖNDEROĞLU Lütfü S., ÖZYÜNCÜ Özgür, SALMAN M. Coşkun, Editor, Güneş Tıp Kitabevi, Ankara, pp.61-80, 2014

Refereed Congress / Symposium Publications in Proceedings

I. **Clozapine and Long-Acting Injectable Antipsychotic Combination: A Retrospective Chart Review.**
MUTLU E., KARAÇAM M., ERTUĞRUL A., ANIL YAĞCIOĞLU A. E.
the 2022 Congress of the Schizophrenia International Research Society (SIRS), Italy, 06 April 2022

Supported Projects

YAZICI M. K., ERDEM Y., KARAHAN S., ÖZÇELİK EROĞLU E., ERTUĞRUL A., ENİ N., AKBIYIK F., SAĞLAM AYKUT D., ANIL YAĞCIOĞLU A. E., Project Supported by Higher Education Institutions, Lityum Karbonat Tedavisinin Böbrek Tiroid ve Paratiroid İşlevleri Üzerindeki Etkisi, 2018 - 2020

Metrics

Publication: 142
Citation (WoS): 1070
Citation (Scopus): 1020
H-Index (WoS): 17
H-Index (Scopus): 17